drugset / Trial / NCT00911625

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

NCT00911625 ↗

Phase 4 Completed 114 enrolled Loyola University Sanofi · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: \< 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.

Timeline

Start
2009-01-21
Primary completion
2011-06-30
Completion
2011-06-30

Outcome

Missed primary endpoint

registry analysis (superiority test); 0.5 Units/kg vs 0.25 Units/kg; p = .958; Mean Difference (Final Values) -0.50 (95% CI -19.341 to 18.341); t-test, 2 sided NCT00911625 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 0.25 units/kg daily insulin Unknown 0.125 iu/kg —
Subject 0.25 units/kg daily insulin Unknown 0.25 iu/kg —
Comparator 0.5 units/kg daily insulin Unknown 0.125 iu/kg —
Comparator 0.5 units/kg daily insulin Unknown 0.25 iu/kg —
Subject insulin glargine Protein / enzyme biologic 0.125 iu/kg —
Subject insulin glargine Protein / enzyme biologic 0.25 iu/kg —